Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagannathan, Prasanna, Andrews, Jason R., Bonilla, Hector, Hedlin, Haley, Jacobson, Karen B., Balasubramanian, Vidhya, Purington, Natasha, Kamble, Savita, de Vries, Christiaan R., Quintero, Orlando, Feng, Kent, Ley, Catherine, Winslow, Dean, Newberry, Jennifer, Edwards, Karlie, Hislop, Colin, Choong, Ingrid, Maldonado, Yvonne, Glenn, Jeffrey, Bhatt, Ami, Blish, Catherine, Wang, Taia, Khosla, Chaitan, Pinsky, Benjamin A., Desai, Manisha, Parsonnet, Julie, Singh, Upinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009873/
https://www.ncbi.nlm.nih.gov/pubmed/33785743
http://dx.doi.org/10.1038/s41467-021-22177-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009873/
https://www.ncbi.nlm.nih.gov/pubmed/33785743
http://dx.doi.org/10.1038/s41467-021-22177-1

Ejemplares similares